Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916Phase 3Recruiting
- Lead sponsor
- Immunovant Sciences GmbH (Industry)
- Enrollment
- 231 (estimated)
- Start date
- 27 May 2025
- Primary completion
- Dec 2027 (estimated)
- Study completion
- 1 Dec 2028
- Last update posted
- 30 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Triple
- Arms
- 3
Interventions
- IMVT-1402 Drug
- Placebo Drug
Conditions and primary outcome
- Generalized Myasthenia Gravis
Primary outcome
Change from Baseline in MG-ADL Score for Antibody-positive Participants (Baseline to Week 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07039916.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07039916 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.